Isotyping and Semi-Quantitation of Monkey Anti-Drug Antibodies by Immunocapture Liquid Chromatography-Mass Spectrometry.
Animals
Antibodies, Monoclonal
/ administration & dosage
Antibodies, Neutralizing
/ blood
Biological Products
/ administration & dosage
Calibration
Chromatography, High Pressure Liquid
/ methods
Drug Evaluation, Preclinical
/ methods
Enzyme-Linked Immunosorbent Assay
Half-Life
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Injections, Intravenous
Macaca fascicularis
Tandem Mass Spectrometry
/ methods
ADA
LC-MS
immunogenicity
isotyping
monoclonal antibody
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
06 01 2021
06 01 2021
Historique:
received:
16
09
2020
accepted:
23
11
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
5
10
2021
Statut:
epublish
Résumé
There is an urgent demand to develop new technologies to characterize immunogenicity to biotherapeutics. Here, we developed an immunocapture LC-MS assay to isotype and semi-quantify monkey anti-drug antibodies (ADAs) to fully human monoclonal antibody (mAb) drugs. ADAs were isolated from serum samples using an immunocapture step with the Fab of the full-length mAb cross-linked to magnetic beads to minimize matrix interference. A positive monoclonal antibody control against the human immunoglobulin kappa light chain was used as a calibration standard for ADA quantitation. The final LC-MS method contains 17 multiple reaction monitoring (MRM) transitions and an optimized 15-min LC method. The results suggested that IgG1 was the most abundant isotype in ADA-positive samples. IgG2 and IgG4 were identified at lower levels, whereas IgG3 and IgA levels were only observed at very minor levels. In addition, levels of total ADA measured by the LC-MS assay were comparable to results obtained using a traditional ligand binding assay (LBA). The LC-MS ADA assay enabled rapid immunogenicity assessment with additional isotype information that LBAs cannot provide.
Identifiants
pubmed: 33404777
doi: 10.1208/s12248-020-00538-w
pii: 10.1208/s12248-020-00538-w
pmc: PMC7788027
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Biological Products
0
Immunoglobulin A
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16Références
Trends Immunol. 2007 Nov;28(11):482-90
pubmed: 17964218
MAbs. 2019 May/Jun;11(4):709-724
pubmed: 30939981
J Immunol. 2011 Jan 1;186(1):341-9
pubmed: 21131427
Biologicals. 2015 Sep;43(5):298-306
pubmed: 26144595
J Immunol. 2017 Jan 1;198(1):82-93
pubmed: 27864476
Self Nonself. 2010 Oct;1(4):314-322
pubmed: 21487506
Clin Exp Allergy. 2009 Apr;39(4):469-77
pubmed: 19222496
Bioanalysis. 2015;7(20):2701-12
pubmed: 26505555
Curr Opin Microbiol. 2012 Jun;15(3):337-47
pubmed: 22770538
Immunochemistry. 1970 Oct;7(10):839-49
pubmed: 4100096
Front Immunol. 2016 Feb 02;7:21
pubmed: 26870037
Immunogenetics. 2014 Jun;66(6):361-77
pubmed: 24811270
J Immunol Res. 2016;2016:7682472
pubmed: 27034966
J Immunol Methods. 2018 Jan;452:73-77
pubmed: 28970009
J Immunol Res. 2016;2016:1298473
pubmed: 27437405
J Pharm Biomed Anal. 2020 Jul 15;186:113329
pubmed: 32371323
AAPS J. 2016 Mar;18(2):395-403
pubmed: 26721560
Front Immunol. 2014 Oct 20;5:520
pubmed: 25368619
Mol Syst Biol. 2008;4:222
pubmed: 18854821
Arthritis Rheumatol. 2015 Dec;67(12):3124-34
pubmed: 26246004
PLoS One. 2019 Oct 16;14(10):e0223899
pubmed: 31618250
Anal Chem. 2014 Mar 4;86(5):2673-80
pubmed: 24506335
J Pharm Sci. 2011 Feb;100(2):354-87
pubmed: 20740683
Bioanalysis. 2017 May;9(9):707-717
pubmed: 28488898
Anal Chem. 2008 Sep 15;80(18):6907-14
pubmed: 18702532